Abstract

Background

Patients with metastatic renal cell carcinoma (mRCC) experience emotional distress and limited supportive care access. This study assesses a mindfulness app’s feasibility, acceptability, and preliminary efficacy in improving emotional symptoms, trait mindfulness, and overall quality of life for patients with mRCC on immunotherapy.

Methods

This multinational study recruited patients with mRCC undergoing immunotherapy from Brazil and the United States. Participants were required to engage in mindfulness app-based activities for 20–30 min daily, at least 4 days per week, over a 4-week period. Assessments were conducted at weeks 0, 2, 4, and 12 to evaluate emotional symptoms (PROMIS-Anxiety and Depression, Fear of Cancer Recurrence-7), fatigue (Brief Fatigue Inventory), trait mindfulness (Mindfulness Attention Awareness Scale), and quality of life (Functional Assessment of Chronic Illness Therapy-General). Self-reported data were used to assess adherence. Linear mixed-effects models were used to evaluate changes over time for the measured outcomes.

Results

Among 50 patients with mRCC, the feasibility of this intervention was demonstrated; 96% of patients were assessed at week 4, with high adherence rates reported by 75% of patients. Participants expressed positive feedback on the smartphone-based approach. Significant improvements were observed in emotional symptoms, fatigue, and quality of life scores from baseline to post-intervention (P = .001 for each), suggesting the positive impact of this intervention.

Conclusion

Our findings provide encouraging evidence for the feasibility and acceptability of a mindfulness app-based intervention among patients with mRCC. This intervention may offer a viable and accessible means of providing psychosocial support to patients with mRCC.

Details

Title
Feasibility and acceptability of a mindfulness app-based intervention among patients with metastatic renal cell carcinoma: a multinational study
Author
Cristiane Decat Bergerot 1 ; Bergerot, Paulo Gustavo 1 ; Philip, Errol J 2 ; Malhotra, Jasnoor 3 ; Castro, Daniela V 3 ; Govindarajan, Ameish 4 ; Fuzita, William Hiromi 1 ; Marcos Vinicius da Silva França 1 ; Andressa Cardoso de Azeredo 1 ; Gabriel Marques dos Anjos 1 ; Romildo de Araujo 1 ; Hsu, JoAnn 3 ; Chawla, Neal 3 ; Chehrazi-Raffle, Alex 3 ; Marco Murilo Buso 1 ; Saab, Bechara 5 ; Carlson, Linda E 6 ; Pal, Sumanta K 3 

 Oncoclinicas&Co—Medica Scientia Innovation Research (MEDSIR) , Sao Paulo, SP 04543-906 , Brazil 
 University of California Los Angeles , Los Angeles, CA 90095 , United States 
 Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center , Duarte, CA 91010 , United States 
 Memorial Sloan Kettering Cancer Center , New York, NY 10065 , United States 
 Mobio Interactive Pte. Ltd. , Gateway West 189720 ,  Singapore 
 Department of Oncology, University of Calgary Cumming School of Medicine , Calgary, Alberta T2N 4N1 ,  Canada 
Publication year
2025
Publication date
Jan 2025
Publisher
Oxford University Press
ISSN
10837159
e-ISSN
1549490X
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3191890943
Copyright
© The Author(s) 2025. Published by Oxford University Press. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.